Background: Compared to Western populations, familial frontotemporal lobar degeneration (FTLD) is rare among Asians. Progranulin (GRN) gene mutation, which is a major cause of FTLD, is likewise rare. We present a family with FTLD from the Philippines with an autosomal dominant pattern of inheritance and GRN mutation and briefly review reports of GRN mutations in Asia. Case Presentation: The proband is 66 years old with progressive nonfluent aphasia (PNFA)-corticobasal syndrome . We assessed 3 generations of her pedigree and found 11 affected relatives with heterogenous phenotypes, usually behavioral variant frontotemporal dementia (FTD) and PNFA. Neuroimaging showed atrophy and hypometabolism consistent with FTD syndromes. White matter hyperintensities were seen in affected members even in the absence of vascular risk factors. A GRN mutation R110X was found in 6 members, 3 with symptoms and 3 were asymptomatic. Plasma GRN was low (<112 ng/mL) in all mutation carriers. No mutations were found in microtubule-associated protein tau, APP, PSEN1, and PSEN2 genes, and all were APOE3. Conclusion: This is the first Filipino family with autosomal dominant FTD documented with GRN mutation. Identifying families and cohorts would contribute to therapeutic developments in an area with FTD-GRN.

1.
Neary
D
,
Brun
A
,
Englund
B
,
Gustafson
L
,
Passant
U
,
Mann
DMA
, et al.
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups
.
J Neurol Neurosurg Psychiatry
.
1994
;
57
(
4
):
416
8
.
2.
Seelaar
H
,
Kamphorst
W
,
Rosso
SM
,
Azmani
A
,
Masdjedi
R
,
de Koning
I
, et al.
Distinct genetic forms of frontotemporal dementia
.
Neurology
.
2008
;
71
(
16
):
1220
6
. .
3.
Pickering-Brown
SM
,
Rollinson
S
,
Du Plessis
D
,
Morrison
KE
,
Varma
A
,
Richardson
AM
, et al.
Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations
.
Brain
.
2008
;
131
(
Pt 3
):
721
31
. .
4.
Rohrer
JD
,
Guerreiro
R
,
Vandrovcova
J
,
Uphill
J
,
Reiman
D
,
Beck
J
, et al.
The heritability and genetics of frontotemporal lobar degeneration
.
Neurology
.
2009
;
73
(
18
):
1451
6
. .
5.
Greaves
CV
,
Rohrer
JD
.
An update on genetic frontotemporal dementia
.
J Neurol
.
2019
;
266
(
8
):
2075
86
. .
6.
Goldman
JS
,
Farmer
JM
,
Wood
EM
,
Johnson
JK
,
Boxer
A
,
Neuhaus
J
, et al.
Comparison of family histories in FTLD subtypes and related tauopathies
.
Neurology
.
2005
;
65
(
11
):
1817
9
. .
7.
Wada-Isoe
K
,
Ito
S
,
Adachi
T
,
Yamawaki
M
,
Nakashita
S
,
Kusumi
M
, et al.
Epidemiological survey of frontotemporal lobar degeneration in tottori prefecture, Japan
.
Dement Geriatr Cogn Dis Extra
.
2012
;
2
(
1
):
381
6
. .
8.
Ghosh
A
,
Dutt
A
,
Ghosh
M
,
Bhargava
P
,
Rao
S
.
Using the revised diagnostic criteria for frontotemporal dementia in India: evidence of an advanced and florid disease
.
PLoS One
.
2013
;
8
(
4
):
e60999
. .
9.
Fukuhara
R
,
Ghosh
A
,
Fuh
JL
,
Dominguez
J
,
Ong
PA
,
Dutt
A
, et al.
Family history of frontotemporal lobar degeneration in Asia: an international multi-center research
.
Int Psychogeriatr
.
2014
;
26
(
12
):
1967
71
. .
10.
Mathew
R
,
Bak
TH
,
Hodges
JR
.
Diagnostic criteria for corticobasal syndrome: a comparative study
.
J Neurol Neurosurg Psychiatry
.
2012
;
83
(
4
):
405
10
. .
11.
Parmera
JB
,
Rodriguez
RD
,
Studart Neto
A
,
Nitrini
R
,
Brucki
SMD
.
Corticobasal syndrome: a diagnostic conundrum
.
Dement Neuropsychol
.
2016
;
10
(
4
):
267
75
. .
12.
Gorno-Tempini
ML
,
Hillis
AE
,
Weintraub
S
,
Kertesz
A
,
Mendez
M
,
Cappa
SF
, et al.
Classification of primary progressive aphasia and its variants
.
Neurology
.
2011
;
76
(
11
):
1006
14
. .
13.
Dominguez
JC
,
Soriano
JR
,
Magpantay
CD
,
Orquiza
MGS
,
Solis
WM
,
Reandelar
MF
 Jr
, et al.
Early detection of mild Alzheimer’ s disease in Filipino elderly : validation of the Montreal cognitive sssessment-Philippines
.
Adv Alzheimer’s Dis
.
2014
;
3
:
160
7
.
14.
Finch
N
,
Baker
M
,
Crook
R
,
Swanson
K
,
Kuntz
K
,
Surtees
R
, et al.
Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members
.
Brain
.
2009
;
132
(
Pt 3
):
583
91
. .
15.
Ikeda
M
,
Ishikawa
T
,
Tanabe
H
.
Epidemiology of frontotemporal lobar degeneration
.
Dement Geriatr Cogn Disord
.
2004
;
17
(
4
):
265
8
. .
16.
Tang
M
,
Gu
X
,
Wei
J
,
Jiao
B
,
Zhou
L
,
Zhou
Y
, et al.
Analyses MAPT, GRN, and C9orf72 mutations in Chinese patients with frontotemporal dementia
.
Neurobiol Aging
.
2016
;
46
:
235
5
. .
17.
Ogaki
K
,
Li
Y
,
Takanashi
M
,
Ishikawa
K
,
Kobayashi
T
,
Nonaka
T
, et al.
Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLD, PSP, and CBS
.
Parkinsonism Relat Disord
.
2013
;
19
(
1
):
15
20
. .
18.
Aswathy
PM
,
Jairani
PS
,
Raghavan
SK
,
Verghese
J
,
Gopala
S
,
Srinivas
P
, et al.
Progranulin mutation analysis: identification of one novel mutation in exon 12 associated with frontotemporal dementia
.
Neurobiol Aging
.
2016
;
39
:
218
3
. .
19.
Kim
EJ
,
Kwon
JC
,
Park
KH
,
Park
KW
,
Lee
JH
,
Choi
SH
, et al.
Clinical and genetic analysis of MAPT, GRN, and C9orf72 genes in Korean patients with frontotemporal dementia
.
Neurobiol Aging
.
2014
;
35
(
5
):
1213
7
. .
20.
Kim
HJ
,
Jeon
BS
,
Yun
JY
,
Seong
MW
,
Park
SS
,
Lee
JY
.
Screening for MAPT and PGRN mutations in Korean patients with PSP/CBS/FTD
.
Parkinsonism Relat Disord
.
2010
;
16
:
305
6
.
21.
Au
LWC
,
Wong
A
,
Abrigo
J
,
Yuen
YP
,
Leung
EYL
,
Mok
VCT
.
Early-onset dementia in chinese: demographic and etiologic characteristics
.
Neurol Asia
.
2019
;
24
:
139
46
.
22.
Masellis
M
,
Momeni
P
,
Meschino
W
,
Heffner
R
,
Elder
J
,
Sato
C
, et al.
Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome
.
Brain
.
2006
;
129
(
Pt 11
):
3115
23
. .
23.
Hosaka
T
,
Ishii
K
,
Miura
T
,
Mezaki
N
,
Kasuga
K
,
Ikeuchi
T
.
A novel frameshift GRN mutation results in frontotemporal lobar degeneration with a distinct clinical phenotype in two siblings: case report and literature review
;
2017
. p.
1
6
.
24.
Vivianna
WVD
,
Elisabeth
W
,
Peachie 
M
,
Mark
YMKLF
,
Christopher
C
,
John
NMT
, et al.
Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations
.
Arch Neurol
.
2007
;
64
:
1148
53
.
25.
Le Ber
I
,
van der Zee
J
,
Hannequin
D
,
Gijselinck
I
,
Campion
D
,
Puel
M
, et al.
Progranulin null mutations in both sporadic and familial frontotemporal dementia
.
Hum Mutat
.
2007
;
28
(
9
):
846
55
. .
26.
Yu
CE
,
Bird
TD
,
Bekris
LM
,
Montine
TJ
,
Leverenz
JB
,
Steinbart
E
, et al.
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration
.
Arch Neurol
.
2010
;
67
(
2
):
161
70
. .
27.
Wauters
E
,
Van Mossevelde
S
,
Sleegers
K
,
van der Zee
J
,
Engelborghs
S
,
Sieben
A
, et al.
Clinical variability and onset age modifiers in an extended Belgian GRN founder family
.
Neurobiol Aging
.
2018
;
67
:
84
94
. .
28.
Mathew
R
,
Bak
TH
,
Hodges
JR
.
Screening for cognitive dysfunction in corticobasal syndrome: utility of addenbrooke’s cognitive examination
.
Dement Geriatr Cogn Disord
.
2011
;
31
:
254
8
.
29.
Gorno-Tempini
ML
,
Dronkers
NF
,
Rankin
KP
,
Ogar
JM
,
Phengrasamy
L
,
Rosen
HJ
, et al.
Cognition and anatomy in three variants of primary progressive aphasia
.
Ann Neurol
.
2004
;
55
(
3
):
335
46
. .
30.
Jacova
C
,
Hsiung
GY
,
Tawankanjanachot
I
,
Dinelle
K
,
McCormick
S
,
Gonzalez
M
, et al.
Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers
.
Neurology
.
2013
;
81
(
15
):
1322
31
. .
31.
Caroppo
P
,
Le Ber
I
,
Camuzat
A
,
Clot
F
,
Naccache
L
,
Lamari
F
, et al.
Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin
.
JAMA Neurol
.
2014
;
71
(
12
):
1562
6
. .
32.
Ameur
F
,
Colliot
O
,
Caroppo
P
,
Ströer
S
,
Dormont
D
,
Brice
A
, et al.
White matter lesions in FTLD: distinct phenotypes characterize GRN and C9ORF72 mutations
.
Neurol Genet
.
2016
;
2
(
1
):
e47
. .
33.
Jackman
K
,
Kahles
T
,
Lane
D
,
Garcia-Bonilla
L
,
Abe
T
,
Capone
C
, et al.
Progranulin deficiency promotes post-ischemic blood-brain barrier disruption
.
J Neurosci
.
2013
;
33
(
50
):
19579
. .
34.
Martens
LH
,
Huang
EJ
,
Jr
RVF
,
Martens
LH
,
Zhang
J
,
Barmada
SJ
, et al.
Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury find the latest version: brief report progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury
.
J Clin Invest
.
2012
;
122
:
3955
9
.
35.
Youn
YC
,
Hsiung
GYR
.
A voxel based morphometric analysis of longitudinal cortical gray matter changes in progranulin mutation carriers at-risk for frontotemporal dementia: preliminary study
.
Dement Neurocognitive Disord
.
2015
;
14
(
4
):
163
. .
36.
Sudre
CH
,
Bocchetta
M
,
Cash
D
,
Thomas
DL
,
Woollacott
I
,
Dick
KM
, et al.
White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort
.
NeuroImage Clin
.
2017
;
15
:
171
80
. .
37.
Rademakers
R
,
Baker
M
,
Gass
J
,
Adamson
J
,
Huey
ED
,
Momeni
P
, et al.
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative
.
Lancet Neurol
.
2007
;
6
:
857
68
.
38.
Kim
EJ
,
Park
KW
,
Lee
JH
,
Choi
S
,
Jeong
JH
,
Yoon
SJ
, et al.
Clinical and neuropsychological characteristics of a nationwide hospital-based registry of frontotemporal dementia patients in Korea: a CREDOS-FTD study
.
Dement Geriatr Cogn Dis Extra
.
2014
;
4
(
2
):
242
51
. .
39.
Gossye
H
,
Van Broeckhoven
C
,
Engelborghs
S
.
The use of biomarkers and genetic screening to diagnose frontotemporal dementia: evidence and clinical implications
.
Front Genet
.
2019
;
10
:
1
18
.
40.
Ng
ASL
,
Tan
YJ
,
Yi
Z
,
Tandiono
M
,
Chew
E
,
Dominguez
J
, et al.
Targeted exome sequencing reveals homozygous TREM2 R47C mutation presenting with behavioral variant frontotemporal dementia without bone involvement
.
Neurobiol Aging
.
2018
;
68
:
e15
160
. .
42.
Prevail therapeutics announces FDA orphan drug designation granted to PR006 for the treatment of patients with frontotemporal dementia with a GRN mutation
.
2019
.
43.
Kansal
K
,
Mareddy
M
,
Sloane
KL
,
Minc
AA
,
Rabins
PV
,
McGready
JB
, et al.
Survival in frontotemporal dementia phenotypes: a meta-analysis
.
Dement Geriatr Cogn Disord
.
2016
;
41
(
1–2
):
109
22
. .
44.
Guven
G
,
Lohmann
E
,
Bras
J
,
Gibbs
JR
,
Gurvit
H
,
Bilgic
B
, et al.
Mutation Frequency of the Major Frontotemporal Dementia Genes, MAPT, GRN and C9ORF72 in a Turkish Cohort of Dementia Patients
.
PLoS One
.
2016
;
11
(
9
):
e0162592
. .
45.
Che
XQ
,
Zhao
QH
,
Huang
Yue
,
Li
X
,
Ren
RJ
,
Chen
SD
, et al.
Genetic Features of MAPT, GRN, C9orf72 and CHCHD10 Gene Mutations in Chinese Patients with Frontotemporal Dementia
.
Curr Alzheimer Res
.
2017
;
14
(
10
):
1102
8
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.